Medulloblastoma

Medulloblastoma

Medulloblastoma is the most common malignant brain tumor in children, accounting for approximately 25% of pediatric central nervous system tumors. It typically arises in the cerebellum in children younger than 10 years and is classified as a WHO grade 4 embryonal tumor. Despite advances in therapy, it carries significant morbidity and mortality, with 5-year survival rates of 65% to 70%. The 2021 WHO classification defines 4 molecular subgroups: WNT-activated, SHH-activated (TP53-wildtype and TP53-mutant), and non-WNT/non-SHH (groups 3 and 4), each with distinct prognostic and clinical features. This activity reviews the clinical presentation, diagnostic evaluation (including neuroimaging and cerebrospinal fluid analysis), and risk-adapted management with surgery, radiation, and chemotherapy. Emphasis is placed on early recognition, molecular classification, interprofessional care, and strategies to reduce treatment-related complications and support long-term outcomes.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.